Fulcrum Therapeutics Stock Analysis

Fulcrum Stock Analysis Notes

About 90.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.86. Some equities with similar Price to Book (P/B) outperform the market in the long run. Fulcrum Therapeutics recorded a loss per share of 0.29. The entity had not issued any dividends in recent years. Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Fulcrum Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 104 people. To learn more about Fulcrum Therapeutics call Bryan Stuart at 617 651 8851 or check out https://www.fulcrumtx.com.

Fulcrum Therapeutics Investment Alerts

Fulcrum Therapeutics Upcoming and Recent Events

Fulcrum Largest EPS Surprises

View All Earnings Estimates

Fulcrum Therapeutics Environmental, Social, and Governance (ESG) Scores

Fulcrum Stock Institutional Investors

Note, although Fulcrum Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Fulcrum Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 225.46 M.

Fulcrum Profitablity

The company has Profit Margin (PM) of (0.25) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.66 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.66.

Management Efficiency

Fulcrum Therapeutics has return on total asset (ROA) of (0.0689) % which means that it has lost $0.0689 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0737) %, meaning that it created substantial loss on money invested by shareholders. Fulcrum Therapeutics' management efficiency ratios could be used to measure how well Fulcrum Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of February 1, 2025, Return On Tangible Assets is expected to decline to -0.36. In addition to that, Return On Capital Employed is expected to decline to -0.43. At present, Fulcrum Therapeutics' Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 3.9 M, whereas Total Assets are forecasted to decline to about 164.9 M.

Technical Drivers

As of the 1st of February, Fulcrum Therapeutics shows the Mean Deviation of 3.18, coefficient of variation of 907.79, and Downside Deviation of 4.1. Fulcrum Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.

Fulcrum Therapeutics Price Movement Analysis

Fulcrum Therapeutics Insider Trading Activities

Fulcrum Therapeutics Outstanding Bonds

Fulcrum Therapeutics Predictive Daily Indicators

Fulcrum Therapeutics Corporate Filings

Fulcrum Therapeutics Forecast Models

Fulcrum Therapeutics' time-series forecasting models are one of many Fulcrum Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Fulcrum Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Fulcrum Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Fulcrum shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Fulcrum Therapeutics. By using and applying Fulcrum Stock analysis, traders can create a robust methodology for identifying Fulcrum entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Fulcrum analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Fulcrum analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Fulcrum Therapeutics stock analysis indicators help investors evaluate how Fulcrum Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Fulcrum Therapeutics shares will generate the highest return on investment. By understating and applying Fulcrum Therapeutics stock analysis, traders can identify Fulcrum Therapeutics position entry and exit signals to maximize returns.

When running Fulcrum Therapeutics' price analysis, check to measure Fulcrum Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulcrum Therapeutics is operating at the current time. Most of Fulcrum Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fulcrum Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulcrum Therapeutics' price. Additionally, you may evaluate how the addition of Fulcrum Therapeutics to your portfolios can decrease your overall portfolio volatility.